Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not sure if this was already posted here. So much for the canine vaccine...https://onlinelibrary.wiley.com/doi/full/10.1111/vco.12642
Overall survival
I called New England Veterinary Oncology Group which was listed last year as one of the participating vets for the AT-014 trial. The person I talked to seemed to know nothing about it. Anyone else know what is going on with the expanded safety trial?
If ADXS-503 can re-sensitize or enhance response to Keytruda, there is a reason Merck might want a deal with Advaxis. It could be good for a lot of indications.
Not specifically about Advaxis but does offer an explanation of why immunotherapy an CIs work in some people and tumors but not others. Advaxis should contact Dr. Schietinger and say, "Hey, maybe we can help here. We have a new HOT treatment that is economical, too! Let's do lunch!"
https://www.cancerresearch.org/blog/february-2020/andrea-schietinger-star-scientist-tox?utm_source=luminate&utm_medium=email&utm_campaign=cancerimmunews&utm_content=mar2020
A bit of buying...
https://fintel.io/sob/us/adxs
Curious to see if HOT will improve on these results alone or in a combo.
It's been a long time since any news or updates have come out. The links to the videos I posted with Dr. Petit were uploaded the end of 2019 and, based on what he said, they are ongoing but I have not seen anything else.
I know. They seem to be taking an eternity. Here's another brief video.
Found this on the OS website:
I can hear several posters gnashing their tooth.
Is there anything to read into today's trading? Pump and dump, news coming, possible partner? I'm not sure what could be new regarding the ADXS-PSA data? Anyone care to comment?
Well, that would seem to be the MO.
Seems like a lot of AM buying today. Not just one spike but consistent. Thoughts?
CVM & NNVC have long languished but now their fortunes may be turning. Maybe this will be ADXS time.
Even though the HOT data will be, I think, a fairly small sample, I'm hoping there will be enough data for Merck to want to make some kind of deal.
I hope the HOT data gives a compelling reason for Merck to want to cut a deal.
If the HOT data is good, especially when combined with Keytruda, I think we may finally see a deal with Merck.
I think Dr. Mason is/was conducting a study before amputation. So many things change with this company, I'm not sure what's going on. I hope they still plan on releasing the cervical results like they said they would.
I think approval should not take a couple of years. They've been in the field study now for some time. Longer than I expected but I hope it comes to its finish soon. It may not explode the stock but it will be considered a win. I hope I can hang on a bit longer.
I am surprised the AT-014 field study has not yet been completed. I understand the need to ensure the safety of the vaccine but I would think, considering it extended survival time by quite a bit, effort would be made to get it approved ASAP.
So, partner next? Could be they were waiting for IND acceptance first.
And to you and yours. And, maybe, a prosperous New Year?
I still have some hope that Merck will partner for prostate. I would think they'd like to corner the market on anything that would help boast Keytruda.
Wash, rinse, repeat with the occasional spin cycle.
Per Short Squeeze:
Short Interest (Shares Short) 706,200
Short % Increase / Decrease -60 %
Short Interest (Shares Short) - Prior 1,760,000
"$.50 cents a share". Do you have any idea what you're talking about?
There is no argument with anything you have stated. In fact, that was perfectly stated.
There is no doubt that the prostate results were good, very good. Given the stated low-cost of goods, stability and ability to start treatment right away, a Big Pharma may take an interest (Merck or others) and look for a deal. We desperately need that. As you noted a myriad of blunders on the part of the company have taken place. I've been so disappointed with how this company has handled things but we may have a last chance here. I certainly hope so.
Considering the financials of the company, I would think 1) they are submitting for the IND and hope to entice a partner or 2) they have a partner lined up. I doubt they could go it alone but who knows. I'm leaning more towards your thinking.
"... will investigate anti-tumor immunity and anti-tumor responses generated by Lm vaccines that express diverse glioblastoma neoantigens".
This could be one of the "10 HOT constructs designed that can be moved into the clinic" (Per the CP). We know an IND is planned for HOT prostate and bladder cancer sometime in the future so that leaves 8 other HOT constructs. Maybe Glio after those.
Still a few catalysts on the CP for 2H 2019:
HOT NSCLC - Immunogenicity data from initial clinical cohort (safety, immune response)
HOT Prostate - IND Submission
HPV - Announce planned Investigator-Sponsored Trials in Head and Neck Cancer (Third Party Funded)
Initiate Phase 2 Study in HPV+Lung Cancer (Taiwan partner funded)
Let's see if they can make it.
Short Interest (Shares Short)
1,760,000
Short Interest Ratio (Days To Cover)
0.3
Short Percent of Float
%
Short % Increase / Decrease
-45 %
Short Interest (Shares Short) - Prior
3,190,000
http://shortsqueeze.com/shortinterest/stock/ADXS.htm
Wednesday used to be there news release day of choice.
I'm watching the volume still climbing. P&D? Not sure. I think, like you, there might be something else (oh, please,please) behind it.
Well, there are a few catalysts due between now and the end of the year. Over 13.5 Mill. shares traded so far.
Just passed 11 mil. shares traded.
Giving us a bit of a lift?
So, less than two months for these:
ADXS-PSA Updated survival data from Part B 2H 2019
ADXS-HOT NSCLC Initiate Part B in combination with checkpoint inhibitor 2H 2019
Immunogenicity data from initial clinical cohort (safety, immune response) 2H 2019
ADXS-504 HOT Prostate IND Submission 2H 2019
ADXS-HPV Announce planned Investigator-Sponsored Trials in Head and Neck Cancer 2H 2019
Initiate Phase 2 Study in HPV+LungCancer (Taiwan partner)2H 2019
Let's see how many they are able provide. We already had a PR for PSA on 10/7. Are we to expect another? I would much rather see unblinded cervical cancer data ASAP.
I think we can all agree that Advaxis threw money away left and right taking on too many trials. Prostate should have been front and center. If HOT can improve on the already very good results with Keytruda, we may get a deal with Merck. It would make sense since Keytruda seems to be enhanced with other treatments.